Evidence map›Paper›PMID 34832885›Full record

ReviewPharmaceuticals (Basel, Switzerland)2021

Polydeoxyribonucleotide: A Promising Biological Platform to Accelerate Impaired Skin Wound Healing.

Mariarosaria Galeano, Giovanni Pallio, Natasha Irrera, Federica Mannino, Alessandra Bitto, Domenica Altavilla, Mario Vaccaro, Giovanni Squadrito, Vincenzo Arcoraci, Michele Rosario Colonna and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 56 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Mariarosaria GaleanoDepartment of Human Pathology and Evolutive Age "Gaetano Barresi", University of Messina, Via C. Valeria, 98125 Messina, Italy.
Giovanni PallioDepartment of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.ORCID 0000-0002-4187-2265
Natasha IrreraDepartment of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.ORCID 0000-0002-1134-7080
Federica ManninoDepartment of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Alessandra BittoDepartment of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Domenica AltavillaSunNutraPharma, Academic Spin-Off Company of the University of Messina, Via C. Valeria, 98125 Messina, Italy.
Mario VaccaroDepartment of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.ORCID 0000-0003-3787-5145
Giovanni SquadritoDepartment of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
Vincenzo ArcoraciDepartment of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.ORCID 0000-0003-0061-0477
Michele Rosario ColonnaDepartment of Human Pathology and Evolutive Age "Gaetano Barresi", University of Messina, Via C. Valeria, 98125 Messina, Italy.ORCID 0000-0001-5586-4066
Rita LauroDepartment of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.ORCID 0000-0001-7183-0288
Francesco SquadritoDepartment of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.ORCID 0000-0002-8868-0762
University of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The normal wound healing process is characterized by a complex, highly integrated cascade of events, requiring the interactions of many cell types, including inflammatory cells, fibroblasts, keratinocytes and endothelial cells, as well as the involvement of growth factors and enzymes. However, several diseases such as diabetes, thermal injury and ischemia could lead to an impaired wound healing process characterized by wound hypoxia, high levels of oxygen radicals, reduced angiogenesis, decreased collagen synthesis and organization. Polydeoxyribonucleotide (PDRN) has been used to improve wound healing through local and systemic administration thanks to its ability to promote cell migration and growth, angiogenesis, and to reduce inflammation on impaired wound healing models in vitro, in vivo and clinical studies. In light of all these observations, the aim of this review is to provide a full overview of PDRN applications on skin regeneration. We reviewed papers published in the last 25 years on PubMed, inserting "polydeoxyribonucleotide and wound healing" as the main search term. All data obtained proved the ability of PDRN in promoting physiological tissue repair through adenosine A

Indexed as

adenosine receptorsPDRNpolydeoxyribonucleotidewound healing

Identifiers

PMID34832885
PMCPMC8618295
OpenAlexW3208112815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.